瑞银集团增持恒瑞医药20.44万股 每股作价约85.88港元

Core Viewpoint - UBS Group has increased its stake in Heng Rui Medicine, acquiring 204,400 shares at a price of HKD 85.8849 per share, totaling approximately HKD 17.55 million, resulting in a new holding of about 18.18 million shares, representing 7.04% ownership [1] Summary by Category Company Actions - UBS Group purchased 204,400 shares of Heng Rui Medicine on September 8 [1] - The acquisition price was HKD 85.8849 per share, leading to a total investment of approximately HKD 17.55 million [1] Ownership Structure - Following the purchase, UBS Group's total holdings in Heng Rui Medicine increased to approximately 18.18 million shares [1] - The new ownership percentage stands at 7.04% [1]